Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1011

  • Filters activated: Field: Title/Abstract. Clear all
1.

The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.

Woo V, Connelly K, Lin P, McFarlane P.

Curr Med Res Opin. 2019 Feb 15:1-13. doi: 10.1080/03007995.2019.1576479. [Epub ahead of print]

PMID:
30767677
2.

Impact of Diabetes Mellitus on Ventricular Structure, Arterial Stiffness, and Pulsatile Hemodynamics in Heart Failure With Preserved Ejection Fraction.

Chirinos JA, Bhattacharya P, Kumar A, Proto E, Konda P, Segers P, Akers SR, Townsend RR, Zamani P.

J Am Heart Assoc. 2019 Feb 19;8(4):e011457. doi: 10.1161/JAHA.118.011457.

3.

Is there a potential association between spironolactone and the risk of new-onset diabetes in a cohort of older patients with heart failure?

Korol S, White M, O'Meara E, Rouleau JL, White-Guay B, Dorais M, Ahmed A, de Denus S, Perreault S.

Eur J Clin Pharmacol. 2019 Feb 13. doi: 10.1007/s00228-018-02615-8. [Epub ahead of print]

PMID:
30758517
4.

Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes.

Martens P, Janssens J, Ramaekers J, Dupont M, Mullens W.

Acta Cardiol. 2019 Feb 8:1-7. doi: 10.1080/00015385.2019.1569313. [Epub ahead of print]

PMID:
30736724
5.

Heart Failure With Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review.

McHugh K, DeVore AD, Wu J, Matsouaka RA, Fonarow GC, Heidenreich PA, Yancy CW, Green JB, Altman N, Hernandez AF.

J Am Coll Cardiol. 2019 Feb 12;73(5):602-611. doi: 10.1016/j.jacc.2018.11.033. Review.

PMID:
30732715
6.

Ethnicity, heart failure, atrial fibrillation and diabetes: collider bias.

Burden AF, Timpson N.

Heart. 2019 Feb 6. pii: heartjnl-2018-314467. doi: 10.1136/heartjnl-2018-314467. [Epub ahead of print] No abstract available.

PMID:
30728157
7.

Heart Failure in the diabetic patient - epidemiology, etiology, prognosis, therapy and the effect of glucose lowering medications.

Bell DSH, Goncalves E.

Diabetes Obes Metab. 2019 Feb 5. doi: 10.1111/dom.13652. [Epub ahead of print] Review.

PMID:
30724013
8.

[The Diabetic Heart and Heart Failure - Update on Mechanisms and Therapy].

Zweck E, Szendrödi J, Kelm M, Roden M.

Dtsch Med Wochenschr. 2019 Feb;144(3):175-179. doi: 10.1055/a-0646-7871. Epub 2019 Jan 31. German.

PMID:
30703836
9.

Heart failure among people with Type 2 diabetes mellitus: real-world data of 289 954 people from a diabetes database.

Stoyanova D, Stratmann B, Schwandt A, Heise N, Mühldorfer S, Ziegelasch HJ, Zimmermann A, Tschoepe D, Holl RW; DPV Initiative.

Diabet Med. 2019 Jan 30. doi: 10.1111/dme.13915. [Epub ahead of print]

PMID:
30701607
10.

Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction.

Rørth R, Dewan P, Kristensen SL, Jhund PS, Petrie MC, Køber L, McMurray JJV.

Clin Res Cardiol. 2019 Jan 28. doi: 10.1007/s00392-019-01415-z. [Epub ahead of print]

PMID:
30689020
11.

Risk of Heart Failure Hospitalization Associated With Cilostazol in Diabetes: A Nationwide Case-Crossover Study.

Wu CK, Lin JW, Wu LC, Chang CH.

Front Pharmacol. 2019 Jan 7;9:1467. doi: 10.3389/fphar.2018.01467. eCollection 2018.

12.

Response by Figtree et al to Letter Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)".

Figtree GA, Rådholm K, Neal B.

Circulation. 2019 Jan 15;139(3):418-419. doi: 10.1161/CIRCULATIONAHA.118.038477. No abstract available.

PMID:
30640545
13.
14.

Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.

Greene SJ, Butler J.

Circulation. 2019 Jan 8;139(2):152-154. doi: 10.1161/CIRCULATIONAHA.118.037599. No abstract available.

PMID:
30615507
15.

Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study).

Huynh T, Harty BJ, Claggett B, Fleg JL, McKinlay SM, Anand IS, Lewis EF, Joseph J, Desai AS, Sweitzer NK, EileenO'Meara, Pitt B, Pfeffer MA, Rouleau JL.

Am J Cardiol. 2019 Feb 15;123(4):611-617. doi: 10.1016/j.amjcard.2018.11.022. Epub 2018 Nov 24.

PMID:
30612727
16.

Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope.

Giugliano D, Meier JJ, Esposito K.

Diabetes Obes Metab. 2019 Jan 4. doi: 10.1111/dom.13629. [Epub ahead of print] Review.

PMID:
30609236
17.

Treatment of diabetes and heart failure: a paradigm shift for cardiologists?

Brochu B, Chan M.

Curr Opin Cardiol. 2019 Mar;34(2):207-212. doi: 10.1097/HCO.0000000000000599.

PMID:
30608252
18.

Aspirin Use and Cardiovascular Outcome in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Population-Based Cohort Study.

Abi Khalil C, Omar OM, Al Suwaidi J, Taheri S.

J Am Heart Assoc. 2018 Nov 6;7(21):e010033. doi: 10.1161/JAHA.118.010033.

19.

Heart Failure in Type 2 Diabetes Mellitus.

Kenny HC, Abel ED.

Circ Res. 2019 Jan 4;124(1):121-141. doi: 10.1161/CIRCRESAHA.118.311371.

PMID:
30605420
20.

Lung ultrasound evaluation of diabetic patients with acute onset dyspnea and its relationship with established markers of heart failure.

Sikdar S, Panja A, Das A, Dey A, Guha S.

Indian Heart J. 2018 Dec;70 Suppl 3:S399-S402. doi: 10.1016/j.ihj.2018.06.003. Epub 2018 Jun 7.

Supplemental Content

Loading ...
Support Center